GUIDELINES IN DERMATOLOGY

gdkapak

REVIEW OF THE CURRENT CLINICAL GUIDELINES IN THE DIAGNOSIS, MANAGEMENT AND FOLLOW-UP OF CUTENEOUS MELANOMA

Sera Nur Yücesoy1
Tuğba Kevser Uzunçakmak2

1Bezmialem Vakıf University, Faculty of Medicine, Department of Dermatology, İstanbul, Türkiye
2İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Dermatology, İstanbul, Türkiye

Yücesoy SN, Uzunçakmak TK. Review of the Current Clinical Guidelines in the Diagnosis, Management and Follow-up of Cuteneous Melanoma. In: Kutlubay Z, editor. Guidelines in Dermatology. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.79-91.

ABSTRACT

Melanoma is the least common type of skin cancer in both men and women, but due to its high risk of metastasis and mortality rates, early diagnosis and treatment is of vital importance for both the clinicians and patients. The diagnosis, management, and follow-up of cutaneous melanoma are pivotal in enhancing patient outcomes and survival rates, given the aggressive nature of this skin cancer. Early and accurate diagnosis is critical, as melanoma’s prognosis is highly dependent on the stage at which it is detected; early-stage melanoma has a significantly higher cure rate compared to advanced stages. Timely diagnosis involves a combination of clinical evaluation, dermatoscopic examination, and histopathological confirmation, which together ensure that the melanoma is accurately staged and characterized. Effective management requires a multidisciplinary approach, integrating surgical excision, potential adjuvant therapies, and personalized treatment plans based on the melanoma’s genetic and molecular profile.

This chapter aims to evaluate evidence-based recommendations for the diagnosis, treatment and follow-up of melanoma under the guidance of current guidelines.

Keywords: BRAF; Cutenous melanoma; Guideline; Immunotherapy; Therapy; Follow-up; Surgery

Referanslar

  1. Markovic SN, Erickson LA, Rao RD, et al. Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007;82(3):364-380. [Crossref]  [PubMed]
  2. Arnold M, Singh D, Laversanne M, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022;158(5):495-503. [Crossref]  [PubMed]  [PMC]
  3. Karimipour DJ, Schwartz JL, Wang TS, et al. Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma. J Am Acad Dermatol. 2005;52(5):798-802. [Crossref]  [PubMed]
  4. Swetter SM, Johnson D, Albertini MR, et al. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024. J Natl Compr Canc Netw. 2024;22(5):290-298. [Link]
  5. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250. [Crossref]  [PubMed]
  6. Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment Update 2022. Eur J Cancer. 2022;170:256-284. [Crossref]  [PubMed]
  7. Bong JL, Herd RM, Hunter JA. Incisional biopsy and melanoma prognosis. J Am Acad Dermatol. 2002;46(5):690-694. [Crossref]  [PubMed]
  8. Martin RC 2nd, Scoggins CR, Ross MI, et al. Is incisional biopsy of melanoma harmful?. Am J Surg. 2005;190(6):913917. [Crossref]  [PubMed]
  9. Bolshinsky V, Lin MJ, Serpell J, et al. Frequency of residual melanoma in wide local excision (WLE) specimens after complete excisional biopsy. J Am Acad Dermatol. 2016;74(1):102-107. [Crossref]  [PubMed]
  10. Saco M, Thigpen J. A retrospective comparison between preoperative and postoperative Breslow depth in primary cutaneous melanoma: how preoperative shave biopsies affect surgical management. J Drugs Dermatol. 2014;13(5):531-536. [PubMed]
  11. Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018;18(8):775-784. [Crossref]  [PubMed]  [PMC]
  12. Smoller BR, Gershenwald JE, Scolyer RA, et al. Protocol for the examination of specimens from patients with melanoma of the skin. Melanoma 4.0.0.0 (Posted June 2017). Based on AJCC/UICC TNM, 8th edition. _ 2017 College of American Pathologists (CAP). [Link]
  13. Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G; ESMO Guidelines Working Group. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v194-v197. [Crossref]  [PubMed]
  14. Australian Cancer Network and New Zealand Guidelines Group. Clinical practice guidelines for the management of melanoma in Australia and New Zealand. Last accessed 24 September 2013. [Link]
  15. Cancer Care Ontario. Screening for skin cancer. [Link]
  16. Sladden MJ, Nieweg OE, Howle J, Coventry BJ, Thompson JF. Updated evidence-based clinical practice guidelines for the diagnosis and management of melanoma: definitive excision margins for primary cutaneous melanoma. Med J Aust. 2018;208(3):137-142. [Crossref]  [PubMed]
  17. Nakamura Y, Asai J, Igaki H, et al. Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019. J Dermatol. 2020;47(2):89-103. [Crossref]  [PubMed]
  18. Fong ZV, Tanabe KK. Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol. 2014;170(1):20-30. [Crossref]  [PubMed]
  19. Kachare SD, Brinkley J, Wong JH, Vohra NA, Zervos EE, Fitzgerald TL. The influence of sentinel lymph node biopsy on survival for intermediate-thickness melanoma. Ann Surg Oncol. 2014;21(11):3377-3385. [Crossref]  [PubMed]
  20. Brănişteanu DE, Cozmin M, Porumb-Andrese E, et al. Sentinel Lymph Node Biopsy in Cutaneous Melanoma, a Clinical Point of View. Medicina (Kaunas). 2022;58(11):1589. Published 2022 Nov 3. [Crossref]  [PubMed]  [PMC]
  21. Tardelli E, Mazzarri S, Rubello D, et al. Sentinel Lymph Node Biopsy in Cutaneous Melanoma: Standard and New Technical Procedures and Clinical Advances. A Systematic Review of the Literature. Clin Nucl Med. 2016;41(12):e498-e507. [Crossref]  [PubMed]
  22. Thompson JF, Cancer Council Australia; Australian Cancer Network; New Zealand, Ministry of Health. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand; Cancer Council Australia: Sydney, Australia, 2008. Accessed on 5 July 2022. [Link]
  23. Thomas JM. Time to re-evaluate sentinel node biopsy in melanoma post-multicenter selective lymphadenectomy trial. J Clin Oncol. 2005;23(36):9443-9444. [Crossref]  [PubMed]
  24. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma [published correction appears in N Engl J Med. 2006 Nov 2;355(18):1944]. N Engl J Med. 2006;355(13):1307-1317. [Crossref]  [PubMed]
  25. Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011;103(2):129-142. [Crossref]  [PubMed]  [PMC]
  26. Voit CA, Oude Ophuis CM, Ulrich J, van Akkooi AC, Eggermont AM. Ultrasound of the sentinel node in melanoma patients: echo-free island is a discriminatory morphologic feature for node positivity. Melanoma Res. 2016;26(3):267-271. [Crossref]  [PubMed]
  27. Voit CA, van Akkooi AC, Schäfer-Hesterberg G, et al. Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma?. J Clin Oncol. 2009;27(30):49945000. [Crossref]  [PubMed]
  28. Wong SL, Faries MB, Kennedy EB, et al. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018;36(4):399-413. [Crossref]  [PubMed]
  29. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 1991;214(4):491-501. [Crossref]  [PubMed]  [PMC]
  30. Farrow NE, Raman V, Williams TP, Nguyen KY, Tyler DS, Beasley GM. Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy. Ann Surg Oncol. 2020;27(13):5121-5125. [Crossref]  [PubMed]  [PMC]
  31. Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757-767. [Crossref]  [PubMed]
  32. Martínez Campayo N, Paradela de la Morena S, Pértega-Díaz S, Tejera Vaquerizo A, Fonseca E. Prognostic significance of sentinel lymph node biopsy in elderly with cutaneous melanoma: systematic review and meta-analysis. Int J Dermatol. 2024;63(7):873-880. [Crossref]  [PubMed]
  33. Torphy RJ, Friedman C, Ho F, et al. Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection. Ann Surg Oncol. 2022;29(2):806-815. [Crossref]  [PubMed]
  34. Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(12):18841901. [Crossref]  [PubMed]
  35. Michielin O, van Akkooi A, Lorigan P, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1449-1461. [Crossref]  [PubMed]
  36. Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13(6):589-597. [Crossref]  [PubMed]
  37. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824-1835. [Crossref]  [PubMed]
  38. Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017;377(19):1813-1823. [Crossref]  [PubMed]
  39. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy [published correction appears in N Engl J Med. 2018 Nov 29;379(22):2185. N Engl J Med. 2016;375(19):1845-1855. [Crossref]  [PubMed]  [PMC]
  40. Liénard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res. 1999;9(5):491-502. [Crossref]  [PubMed]
  41. Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial [published correction appears in Lancet Oncol. 2021 Oct;22(10):e428.doi: 10.1016/S1470-2045(21)00537-4.]. Lancet Oncol. 2020;21(11):1465-1477. [Crossref]  [PubMed]
  42. Minniti G, Anzellini D, Reverberi C, et al. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity. J Immunother Cancer. 2019;7(1):102. Published 2019 Apr 11. [Crossref]  [PubMed]  [PMC]
  43. Glitza Oliva IC, Schvartsman G, Tawbi H. Advances in the systemic treatment of melanoma brain metastases. Ann Oncol. 2018;29(7):1509-1520. [Crossref]  [PubMed]
  44. Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863-873. [Crossref]  [PubMed]
  45. Tawbi HA, Forsyth PA, Hodi FS, et al. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro Oncol. 2021;23(11):1961-1973. [Crossref]  [PubMed]  [PMC]
  46. Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist. 2007;12(9):1114-1123. [Crossref]  [PubMed]
  47. Jiang G, Li RH, Sun C, Liu YQ, Zheng JN. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis. PLoS One. 2014;9(12):e111920. Published 2014 Dec 11. [Crossref]  [PubMed]  [PMC]
  48. Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol. 2008;19(6):1195-1201. [Crossref]  [PubMed]
  49. Hansson J, Aamdal S, Bastholt L, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol. 2011;12(2):144-152. [Crossref]  [PubMed]
  50. Grob JJ, Dreno B, de la Salmonière P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351(9120):1905-1910. [Crossref]  [PubMed]
  51. Ives NJ, Suciu S, Eggermont AMM, et al. Adjuvant interferon- for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017;82:171-183. [Crossref]  [PubMed]
  52. Kirkwood JM, Ibrahim JG, Sondak VK, et al. Highand low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444-2458. [Crossref]  [PubMed]
  53. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001;358(9285):866-869. [Crossref]  [PubMed]
  54. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22(1):53-61. [Crossref]  [PubMed]
  55. Eggermont AM, Suciu S, Rutkowski P, et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer. 2016;55:111-121. [Crossref]  [PubMed]
  56. McMasters KM, Egger ME, Edwards MJ, et al. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. J Clin Oncol. 2016;34(10):1079-1086. [Crossref]  [PubMed]  [PMC]
  57. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma [published correction appears in N Engl J Med. 2010 Sep 23;363(13):1290]. N Engl J Med. 2010;363(8):711-723. [Crossref]  [PubMed]  [PMC]
  58. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526. [Crossref]  [PubMed]
  59. Eggermont AM, Chiarion-Sileni V, Grob JJ. Correction to Lancet Oncol 2015 16: 522-30. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(6):e262. [Crossref]  [PubMed]
  60. Squibb ER. Sons, LLC. Prescribing information: YERVOY® (ipilimumab) injection, for intravenous use. 2018. Accessed Oct 15, 2018. [Link]
  61. Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist. 2013;18(6):733-743. [Crossref]  [PubMed]  [PMC]
  62. Gellrich FF, Schmitz M, Beissert S, Meier F. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update. J Clin Med. 2020;9(1):223. Published 2020 Jan 14. [Crossref]  [PubMed]  [PMC]
  63. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2016;27(7):1362. [Crossref]  [PubMed]  [PMC]
  64. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol. 2004;5(11):875885. [Crossref]  [PubMed]
  65. Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85. Published 2012 Jul 9. [Crossref]  [PubMed]  [PMC]
  66. Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial [published correction appears in Lancet Oncol. 2018 Apr;19(4):e184. doi: 10.1016/S14702045(18)30209-2.]. Lancet Oncol. 2018;19(4):510-520. [Crossref]  [PubMed]
  67. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13(3):205-220. [Crossref]  [PubMed]
  68. Steeb T, Wessely A, Petzold A, et al. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis. Eur J Cancer. 2021;157:348-357. [Crossref]  [PubMed]
  69. Andtbacka RHI, Chastain M, Li A, et al. Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL). ASCO Meeting Abstracts. 2015;33:TPS9094. [Crossref]
  70. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763-5771. [Crossref]  [PubMed]
  71. Stahlie EHA, Franke V, Zuur CL, et al. T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model. Cancer Immunol Immunother. 2021;70(8):2291-2300. [Crossref]  [PubMed]  [PMC]
  72. Gangi A, Zager JS. The safety of talimogene laherparepvec for the treatment of advanced melanoma. Expert Opin Drug Saf. 2017;16(2):265-269. [Crossref]  [PubMed]
  73. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015;33(25):27802788. [Crossref]  [PubMed]
  74. Weide B, Derhovanessian E, Pflugfelder A, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer. 2010;116(17):4139-4146. [Crossref]  [PubMed]
  75. Byers BA, Temple-Oberle CF, Hurdle V, McKinnon JG. Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review. J Surg Oncol. 2014;110(6):770775. [Crossref]  [PubMed]
  76. Temple-Oberle CF, Byers BA, Hurdle V, Fyfe A, McKinnon JG. Intra-lesional interleukin-2 therapy for in transit melanoma. J Surg Oncol. 2014;109(4):327-331. [Crossref]  [PubMed]
  77. Sloot S, Rashid OM, Sarnaik AA, Zager JS. Developments in Intralesional Therapy for Metastatic Melanoma. Cancer Control. 2016;23(1):12-20. [Crossref]  [PubMed]  [PMC]
  78. Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol. 1993;19(11):985-990. [Crossref]  [PubMed]
  79. Cohen MH, Jessup JM, Felix EL, Weese JL, Herberman RB. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer. 1978;41(6):2456-2463. [Crossref]  [PubMed]
  80. Benitez MLR, Bender CB, Oliveira TL, Schachtschneider KM, Collares T, Seixas FK. Mycobacterium bovis BCG in metastatic melanoma therapy. Appl Microbiol Biotechnol. 2019;103(19):7903-7916. [Crossref]  [PubMed]
  81. Kremenovic M, Schenk M, Lee DJ. Clinical and molecular insights into BCG immunotherapy for melanoma. J Intern Med. 2020;288(6):625-640. [Crossref]  [PubMed]
  82. Rosenberg SA, Rapp HJ. Intralesional immunotherapy of melanoma with BCG. Med Clin North Am. 1976;60(3):419-430. [Crossref]  [PubMed]
  83. Thompson JF, Agarwala SS, Smithers BM, et al. Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. Ann Surg Oncol. 2015;22(7):2135-2142. [Crossref]  [PubMed]  [PMC]
  84. Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res. 2008;18(6):405-411. [Crossref]  [PubMed]
  85. Ross MI. Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma. J Surg Oncol. 2014;109(4):314-319. [Crossref]  [PubMed]
  86. Read T, Noonan C, David M, et al. A systematic review of non-surgical treatments for lentigo maligna. J Eur Acad Dermatol Venereol. 2016;30(5):748-753. [Crossref]  [PubMed]
  87. Strom T, Caudell JJ, Han D, et al. Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer. 2014;120(9):1369-1378. [Crossref]  [PubMed]  [PMC]
  88. Wasif N, Gray RJ, Pockaj BA. Desmoplastic melanoma the step-child in the melanoma family?. J Surg Oncol. 2011;103(2):158-162. [Crossref]  [PubMed]
  89. Foote MC, Burmeister B, Burmeister E, Bayley G, Smithers BM. Desmoplastic melanoma: the role of radiotherapy in improving local control. ANZ J Surg. 2008;78(4):273-276. [Crossref]  [PubMed]
  90. Rule WG, Allred JB, Pockaj BA, et al. Results of NCCTG N0275 (Alliance) a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma. Cancer Med. 2016;5(8):1890-1896. [Crossref]  [PubMed]  [PMC]
  91. Patel SP, Othus M, Chen Y, et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023;388(9):813-823. [Crossref]  [PubMed]  [PMC]
  92. Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):11781188. [Crossref]  [PubMed]
  93. Versluis JM, Menzies AM, Sikorska K, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol. 2023;34(4):420-430. [Crossref]  [PubMed]